BioCryst Pharmaceuticals Inc. (BCRX)

3.62
0.01 0.28
NASDAQ : Health Technology
Prev Close 3.63
Open 3.67
Day Low/High 3.56 / 3.70
52 Wk Low/High 2.80 / 9.95
Volume 1.63M
Avg Volume 2.18M
Exchange NASDAQ
Shares Outstanding 110.31M
Market Cap 400.44M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Commit To Buy BioCryst Pharmaceuticals At $3, Earn 10.7% Using Options

Commit To Buy BioCryst Pharmaceuticals At $3, Earn 10.7% Using Options

Investors considering a purchase of BioCryst Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.

BioCryst Pharmaceuticals Becomes Oversold (BCRX)

BioCryst Pharmaceuticals Becomes Oversold (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of BCRX August 18th Options Trading

First Week of BCRX August 18th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the August 18th expiration.

Biotech Movers: BioCryst, Omeros, Radius Health

Biotech Movers: BioCryst, Omeros, Radius Health

BioCryst Pharmaceuticals, Omeros and Radius Health were among the were among the biotech stock movers in premarket trading on July 3.

Biotech Movers: Loxo, NewLink, BioCryst

Biotech Movers: Loxo, NewLink, BioCryst

Loxo Oncology, NewLink Genetics and BioCryst Pharmaceuticals were among the biotech movers in premarket trading on Monday.

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday.

BioCryst Reports Additional Positive Results From The Second Interim Analysis Of Its APeX-1 Trial

125 mg dose of BCX7353 showed a reduction of 73% in overall attack rate (p=0.002)

BioCryst Pharmaceuticals Enters Oversold Territory (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of BCRX December 15th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the December 15th expiration.

TheStreet Quant Rating: D- (Sell)